Lilly is buying narcolepsy drug developer Centessa for up to $7.8 billion

Eli Lilly is acquiring Centessa Pharmaceuticals, a company developing treatments for narcolepsy and other sleep-wake disorders, for up to $7.8 billion ^[1]. The deal, reported March 31, 2026, extends Lilly's move into sleep medicine, a field it entered commercially through the sleep apnea indication for Zepbound ^[1].

Centessa is working on orexin receptor 2 agonists, drugs aimed at conditions including narcolepsy and idiopathic hypersomnia, which MarketWatch described as forms of daytime sleepiness ^[1]. Its most advanced candidate is called cleminorexton, which is currently in Phase 2 clinical trials for three conditions ^[1]. The article did not name those three conditions or say when trial results are expected.

What is known about the money

The $7.8 billion is a maximum figure ^[1]. How that total breaks down has not been reported. It has not been disclosed how much would be paid up front, how much depends on future milestones, or whether the consideration is cash, stock or a mix. The expected closing date was not reported, and it is not yet known whether the transaction still requires shareholder or regulatory approvals.

MarketWatch described the purchase as part of a broader "dealmaking spree" by Lilly ^[1]. The report connects the purchase to Lilly's existing commercial presence in sleep medicine, which the company built through Zepbound's approval for sleep apnea ^[1]. Zepbound is a tirzepatide drug; the Centessa candidate targets orexin receptors rather than the GLP-1 pathway.

Why it matters for patients

Nothing changes today for people taking a GLP-1 or related medication. Ozempic, Wegovy and Rybelsus (semaglutide), Mounjaro and Zepbound (tirzepatide), and Foundayo (orforglipron) are not affected by this acquisition, and no approved product is being withdrawn or changed.

For people living with narcolepsy or idiopathic hypersomnia, the deal is a sign of larger investment in the category, but cleminorexton is still in mid-stage testing. A Phase 2 drug is not approved by the Food and Drug Administration and is not available by prescription ^[1]. Whether cleminorexton works, and how well it works compared with existing options, has not been reported in the article.

The price of any future narcolepsy treatment, whether insurers would cover it, and when it might reach the market have not been disclosed. Those details typically emerge only after late-stage trials and a regulatory review, neither of which appears to have happened yet ^[1].

It is also worth separating the two sleep conditions involved. Zepbound's cleared use is sleep apnea, a breathing disorder. Centessa's program targets narcolepsy and idiopathic hypersomnia, which the report describes as forms of daytime sleepiness ^[1]. MarketWatch did not report that the two conditions are treated with the same drugs, or that GLP-1 medications play a role in narcolepsy care.

What happens next

The acquisition was reported on March 31, 2026 ^[1]. Terms beyond the $7.8 billion maximum, including the upfront portion and the closing timeline, have not been reported. There is no announced date for Phase 2 data on cleminorexton, and it is not yet known which of the three conditions being studied might move to a larger trial first ^[1].

Lilly has not said publicly, in the reporting available, how a narcolepsy drug would fit alongside its existing sleep apnea business, or whether the two would be studied together.